department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Abraxane · pharmadog

pharmadog
drugs
Abraxane

drug

patient view →

paclitaxel albumin bound

Marketedupdated 2mo ago

by Celgene Corp

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 109 investigational indications.

indications

investigational

NSCLCBreast Cancer

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Abraxane

generic

paclitaxel

MOA

Tubulin inhibitor

indication

Non-Small Cell Lung Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 13, 2026

37 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Jul 12, 2034patentUS 9511046*PED
Jan 12, 2034method-of-use (U-1434)US 9511046
Sep 4, 2032patentUS 9393318*PED
Sep 4, 2032patentUS 9597409*PED
Mar 4, 2032method-of-use (U-1290)US 9393318
Mar 4, 2032method-of-use (U-1290)US 9597409
Feb 13, 2027patentUS 8034375*PED221d
Aug 21, 2026patentUS 7758891*PED45d
Aug 21, 2026patentUS 8268348*PED45d
Aug 21, 2026patentUS 9101543*PED45d
Aug 13, 2026method-of-use (U-1290)US 803437537d
Feb 21, 2026method-of-use (U-1434)US 7758891
Feb 21, 2026method-of-use (U-1290)US 8268348
Feb 21, 2026method-of-use (U-1434)US 9101543

Data sources

ClinicalTrials.gov

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

drugpaclitaxel36 co-mentions · 27 sources
drugSOR-00736 co-mentions · 27 sources
tagAdCom28 co-mentions · 25 sources
tagPMA Approval28 co-mentions · 25 sources
company$BSXBOSTON SCIENTIFIC CORP5 co-mentions · 5 sources
tagOncology3 co-mentions · 1 sources
companyBaxter Healthcare Corp1 co-mentions · 1 sources
companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources

Trials studying paclitaxel albumin bound

phase2A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancerrecruitingn=125
phase3Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinomaactive not recruitingn=610
N/AEVERO Drug-coated Balloon (DCB) Randomized Trialrecruitingn=410
phase3Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancerrecruitingn=1,260
phase2Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Caactive not recruitingn=46
phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancerrecruitingn=480
phase2A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancerterminatedn=30
phase2A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)completedn=468

more trials →